In a recent article published by My Company Polska—one of Poland’s leading business magazines—the untapped potential of mushrooms took center stage. The piece explores how compounds derived from fungi may soon transition from foraging baskets to pharmaceutical pipelines.
The article discusses several developments, including efforts to isolate bioactive compounds from species such as Pseudoplectania nigrella, a potential candidate for a new-generation antibiotic. It also highlights the growing presence of mushroom-inspired dietary supplements rooted in traditional Chinese medicine and natural therapies.
While food supplements aren’t subject to clinical trials, the pharmaceutical use of mushroom-based compounds is a different story. Once these ingredients are considered for medicinal products, rigorous testing and regulatory pathways—including clinical trials—are essential.
At Axcellant, we’re closely monitoring the evolution of this space. Whether we’re examining classic small molecules or nature-derived innovations, translating scientific potential into real-world therapies always begins with a strong clinical foundation.
Read the full article in My Company Polska (in Polish).
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant